Zydus MD On Pipeline-In-A-Drug Approach, Partnering Intent

Zydus Lifesciences Limited has been expanding the number of indications for which its novel molecules are being studied as it follows the "pipeline-in-a-drug" model successfully implemented by others like Abbott for Humira (adalimumab) and Sanofi and Regeneron Pharmaceuticals, Inc. for Dupixent (dupilumab).

While the approach has created multibillion-dollar drugs in developed economies like the US, in growing economies like India, where affordability...